Dr. Lisa M. Arkin, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 169
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Perelman School of Med at the University of Pennsylvania
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
WI license 65695-20 -
Pediatrics Physician
PA license MT194861
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Wi Hospitals & Clinics Authority Madison, WI
Medical groups
- University of Wisconsin Medical Foundation Inc (2,553 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 169
- Services billed
- 476
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Application of ultraviolet light to skin | 134 | 28 |
| Destruction of precancer skin growth, 2-14 growths | 80 | 21 |
| Established patient office or other outpatient visit, 20-29 minutes | 59 | 56 |
| Established patient office or other outpatient visit, 30-39 minutes | 53 | 46 |
| Destruction of precancer skin growth, 1 growth | 44 | 43 |
| New patient office or other outpatient visit, 30-44 minutes | 43 | 43 |
| Biopsy of related skin growth, first growth | 38 | 36 |
| New patient office or other outpatient visit, 45-59 minutes | 33 | 33 |
| Destruction of skin growth, 1-14 growths | 26 | 26 |
| Biopsy of related skin growth, each additional growth | 18 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Triamcinolone Acetonide Other prescribers in Madison, WI | 23 |
| Clobetasol Propionate Other prescribers in Madison, WI | 21 |
| Ketoconazole Other prescribers in Madison, WI | 20 |
| Minoxidil Other prescribers in Madison, WI | 16 |
| Dupixent Syringe (dupilumab) Other prescribers in Madison, WI | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 13 payments worth $19,054 in total to this clinician.
| Eli Lilly and Company | $18,801 |
|---|---|
| Chiesi USA, Inc. | $162 |
| Regeneron Pharmaceuticals, Inc. | $46.32 |
| Mallinckrodt Hospital Products Inc. | $28.57 |
| Verrica Pharmaceuticals Inc. | $17.24 |
| Consulting Fee | $17,100 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,350 |
| Travel and Lodging | $318 |
| Food and Beverage | $286 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Dec 17, 2025 | Consulting Fee OLUMIANT · Immunology | $8,100 |
| Eli Lilly and Company Dec 17, 2025 | Consulting Fee OLUMIANT · Immunology | $3,150 |
| Eli Lilly and Company Mar 21, 2025 | Consulting Fee OLUMIANT · Immunology | $3,150 |
| Eli Lilly and Company Mar 21, 2025 | Consulting Fee OLUMIANT · Immunology | $2,700 |
| Eli Lilly and Company Mar 28, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,350 |
| Eli Lilly and Company Nov 22, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $318 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $37,938 in research payments for these studies, mostly to the institutions running them.
- A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company · Recruiting · NCT05723198 - A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
Amgen Inc. - A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.